Charles Schwab
CSTL icon

Charles Schwab’s Castle Biosciences CSTL Stock Holding History

Charles Schwab’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07M Buy
254,535
+12,655
+5% +$282K ﹤0.01% 2388
2026
Q1 		$5.94M Sell
241,880
-655
-0.3% -$21.5K ﹤0.01% 2333
2025
Q4 		$9.43M Buy
242,535
+4,381
+2% +$141K ﹤0.01% 2171
2025
Q3 		$5.42M Buy
238,154
+3,139
+1% +$63.8K ﹤0.01% 2402
2025
Q2 		$4.8M Sell
235,015
-7,243
-3% -$134K ﹤0.01% 2349
2025
Q1 		$4.85M Sell
242,258
-16,608
-6% -$411K ﹤0.01% 2284
2024
Q4 		$6.9M Sell
258,866
-15,895
-6% -$484K ﹤0.01% 2181
2024
Q3 		$7.84M Buy
274,761
+39,417
+17% +$1M ﹤0.01% 2156
2024
Q2 		$5.12M Buy
235,344
+30,407
+15% +$678K ﹤0.01% 2349
2024
Q1 		$4.54M Sell
204,937
-2,358
-1% -$51.3K ﹤0.01% 2325
2023
Q4 		$4.47M Buy
207,295
+6,306
+3% +$111K ﹤0.01% 2358
2023
Q3 		$3.39M Buy
200,989
+14,994
+8% +$262K ﹤0.01% 2424
2023
Q2 		$2.55M Buy
185,995
+2,329
+1% +$47.2K ﹤0.01% 2477
2023
Q1 		$4.17M Sell
183,666
-870
-0.5% -$21.3K ﹤0.01% 2287
2022
Q4 		$4.34M Buy
184,536
+6,910
+4% +$160K ﹤0.01% 2290
2022
Q3 		$4.63M Buy
177,626
+6,585
+4% +$185K ﹤0.01% 2250
2022
Q2 		$3.75M Buy
171,041
+4,928
+3% +$115K ﹤0.01% 2308
2022
Q1 		$7.45M Buy
166,113
+4,198
+3% +$173K ﹤0.01% 2094
2021
Q4 		$6.94M Buy
161,915
+3,492
+2% +$182K ﹤0.01% 2188
2021
Q3 		$10.5M Buy
158,423
+25,170
+19% +$1.77M ﹤0.01% 1978
2021
Q2 		$9.77M Buy
133,253
+16,606
+14% +$1.1M ﹤0.01% 2016
2021
Q1 		$7.99M Buy
116,647
+11,595
+11% +$871K ﹤0.01% 2073
2020
Q4 		$7.05M Buy
105,052
+19,526
+23% +$1.06M ﹤0.01% 2052
2020
Q3 		$4.4M Buy
85,526
+62,304
+268% +$2.77M ﹤0.01% 2126
2020
Q2 		$876K Buy
23,222
+620
+3% +$21.2K ﹤0.01% 2659
2020
Q1 		$674K Buy
22,602
+12,267
+119% +$370K ﹤0.01% 2604
2019
Q4 		$356K Buy
+10,335
New +$253K ﹤0.01% 2933

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's CSTL Position: Q2 2026 in Review

Charles Schwab increased its Castle Biosciences (CSTL) stake by 5.2% in Q2 2026, buying an estimated $282K and bringing the position to 254,535 shares worth $6.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Charles Schwab first reported a position in CSTL in Q4 2019 and has held it in 27 quarters since. The position peaked at $10.5M in Q3 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Charles Schwab held 254,535 shares of Castle Biosciences worth $6.07M as of Q2 2026.
  • Charles Schwab bought 12,655 Castle Biosciences shares in Q2 2026, an estimated $282K.
  • Castle Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2388 holding.
  • Charles Schwab first reported a position in Castle Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Charles Schwab's Castle Biosciences position peaked at $10.5M in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.